NASDAQ:ABUS Arbutus Biopharma Q2 2026 Earnings Report $4.34 -0.07 (-1.59%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$4.32 -0.01 (-0.35%) As of 07/31/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Arbutus Biopharma EPS ResultsActual EPSN/AConsensus EPS -$0.02Beat/MissN/AOne Year Ago EPSN/AArbutus Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$0.70 millionBeat/MissN/AYoY Revenue GrowthN/AArbutus Biopharma Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Arbutus Biopharma Earnings HeadlinesArbutus Biopharma (NASDAQ:ABUS) Stock Crosses Above Two Hundred Day Moving Average - What's Next?July 24, 2026 | americanbankingnews.comArbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces ...July 16, 2026 | markets.businessinsider.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.August 1 at 1:00 AM | Weiss Ratings (Ad)Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to ShareholdersJuly 16, 2026 | globenewswire.comArbutus Biopharma: Moderna Validates My IP Bull CaseJuly 13, 2026 | seekingalpha.comArbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value BenchmarksJuly 9, 2026 | finance.yahoo.comSee More Arbutus Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email. Email Address About Arbutus BiopharmaArbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core. In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics. This LNP platform underpins the company’s RNAi assets and has been the foundation for collaborations with other biopharmaceutical organizations seeking efficient delivery systems for mRNA and RNA-based medicines. Arbutus’ focus on innovative delivery solutions complements its antiviral drug discovery capabilities, positioning it at the forefront of HBV research and development. Founded through the merger of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus maintains dual operations in Warminster, Pennsylvania, and Vancouver, British Columbia. The company’s leadership team combines experience in virology, lipid chemistry and pharmaceutical development, supporting strategic alliances with academic institutions and contract research organizations worldwide. Arbutus continues to engage with global regulatory authorities to advance its clinical trials and seeks partnerships to broaden the reach of its potential HBV therapies.View Arbutus Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Chevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance ProblemMicrosoft Just Flipped the AI Spending Narrative OvernightEveryone’s Focused on China—But That’s Not ASML’s Biggest RiskL3Harris’ Record Backlog Makes Its Stock Sell-Off Look OverdoneQuantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far Upcoming Earnings Booking (8/3/2026)Marriott International (8/3/2026)Diamondback Energy (8/3/2026)ONEOK (8/3/2026)Williams Companies (8/3/2026)Mitsubishi UFJ Financial Group (8/3/2026)Vertex Pharmaceuticals (8/3/2026)Palantir Technologies (8/3/2026)Spotify Technology (8/4/2026)SpaceX (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
